Clearside BioMedical, Inc. (CLSD) Analysts See $-0.69 EPS

February 23, 2018 - By simple simple

 Clearside BioMedical, Inc. (CLSD) Analysts See $ 0.69 EPS

Analysts expect Clearside BioMedical, Inc. (NASDAQ:CLSD) to report $-0.69 EPS on March, 13.They anticipate $0.24 EPS change or 53.33 % from last quarter’s $-0.45 EPS. After having $-0.72 EPS previously, Clearside BioMedical, Inc.’s analysts see -4.17 % EPS growth. The stock decreased 1.71% or $0.11 during the last trading session, reaching $6.32. About 183,288 shares traded or 7.93% up from the average. Clearside BioMedical, Inc. (NASDAQ:CLSD) has 0.00% since February 23, 2017 and is . It has underperformed by 16.70% the S&P500.

Clearside BioMedical, Inc. (NASDAQ:CLSD) Ratings Coverage

Among 4 analysts covering Clearside Biomedical (NASDAQ:CLSD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Clearside Biomedical had 5 analyst reports since June 27, 2016 according to SRatingsIntel. Needham initiated the shares of CLSD in report on Tuesday, June 28 with “Buy” rating. Stifel Nicolaus initiated Clearside BioMedical, Inc. (NASDAQ:CLSD) on Monday, June 27 with “Buy” rating. Stifel Nicolaus maintained Clearside BioMedical, Inc. (NASDAQ:CLSD) rating on Monday, October 24. Stifel Nicolaus has “Buy” rating and $23 target. The firm has “Outperform” rating given on Monday, June 27 by Cowen & Co. The firm has “Outperform” rating given on Monday, June 27 by Wedbush.

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops first-in-class drug therapies to treat blinding diseases of the eye. The company has market cap of $160.16 million. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion ; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase I/II clinical trial for diabetic macular edema (DME). It currently has negative earnings. The company's pre-clinical development program for axitinib for the treatment of wet age-related macular degeneration (wet AMD).

More notable recent Clearside BioMedical, Inc. (NASDAQ:CLSD) news were published by: Globenewswire.com which released: “Clearside Biomedical, Inc. Announces Changes to its Board of Directors” on August 08, 2017, also Globenewswire.com with their article: “Clearside Biomedical, Inc. Redirects Pre-Clinical AMD Research Resources …” published on February 27, 2017, Globenewswire.com published: “Clearside Biomedical, Inc. Announces Third Quarter 2017 Financial Results and …” on November 08, 2017. More interesting news about Clearside BioMedical, Inc. (NASDAQ:CLSD) were released by: Globenewswire.com and their article: “Clearside Biomedical, Inc. to Report Second Quarter 2017 Financial Results on …” published on August 02, 2017 as well as Globenewswire.com‘s news article titled: “Clearside Biomedical, Inc. Announces Completion of Patient Enrollment in Phase …” with publication date: April 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.